SYMBRAVO

Growth

meloxicam, rizatriptan

Axsome Therapeutics

NDAORALTABLET

Approved

Jan 2025

Lifecycle

Growth

Competitive Pressure

0/100

Mechanism of Action

Cyclooxygenase Inhibitors

Pharmacologic Class:

Nonsteroidal Anti-inflammatory Drug

Loss of Exclusivity

LOE Date

Mar 10, 2045

231 months away

Patent Expiry

Mar 10, 2045

Exclusivity Expiry

Jan 30, 2028

Patent Records (5)

Patent #	Expiry	Type	Use Code
11738085	Apr 11, 2036		U-1719
11607456	Apr 11, 2036		U-1719
11571428	Apr 11, 2036		U-1719
11471465	Apr 11, 2036		U-1719
10780166	Apr 11, 2036		U-1719

Company

Axsome Therapeutics

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers